Advertisement

Advertisement
Lung Cancer

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement...

Immunotherapy

FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection

The U.S. Food and Drug Administration (FDA) approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection...

Lung Cancer

Perioperative Nivolumab May Improve Event-Free Survival Compared With Neoadjuvant Nivolumab Plus Chemotherapy Alone in Patients With Resectable NSCLC

Adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery may be effective at reducing the risk of disease recurrence...


Advertisement
Lung Cancer

Using TROP2 Expression to Predict Outcomes in Advanced NSCLC

Researchers have uncovered that TROP2 expression as measured by quantitative continuous scoring may be a predictor of clinical outcomes...

 

Lung Cancer

NeoCOAST-2 Trial: Durvalumab Plus Novel Agents May Increase Pathologic Responses in Resectable NSCLC

The combination of durvalumab with the TROP2-directed antibody-drug conjugate datopotamab deruxtecan may yield high pathologic complete response...

Advertisement
Advertisement




Sponsored Content

SPONSORED BY THE BREAST CANCER INDEX® TEST BIOTHERANOSTICS, INC. A HOLOGIC COMPANY

Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-Making

More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Geriatric Oncology

Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults

Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...

Advertisement

FDA Seeks Consumer Representatives for the Oncologic Drugs Advisory Committee

The U.S. Food and Drug Administration (FDA) is seeking consumer representatives to serve on the Oncologic Drugs Advisory Committee (ODAC).    A consumer representative must be able to analyze scientific data, understand research design, discuss benefits and risks, and evaluate the safety and...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Global Cancer Care

IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting

It happened! We received the International Development and Education Award (IDEA) from Conquer Cancer®, the ASCO Foundation, and it was a journey of growth, global collaboration, leadership, mentorship, and more. We have much to share after this breakthrough in our careers. The ASCO Annual Meeting...

Breast Cancer

A Diagnosis of Triple-Negative Breast Cancer Was Not on My Radar

Despite the fact that there is no history of breast cancer in my family, I didn’t take that good fortune for granted and was diligent about getting my regularly scheduled mammograms and clinical breast exams, which never found any hint of disease. So, it was especially frightening when, while on a...

FDA Approves Atezolizumab and Hyaluronidase-tqjs for Subcutaneous Injection

The U.S. Food and Drug Administration (FDA) approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq), including non–small cell lung cancer (NSCLC), small cell lung cancer...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Cardio-oncology
Lymphoma

New Studies Explore Relationships Between Heart Failure and Lymphoma, Arterial Thromboembolism and Cancer

In two studies recently reported in JACC: CardioOncology, Upshaw and colleagues1 examined the impact of preexisting heart failure on mortality in older patients in the United States with newly diagnosed Hodgkin lymphoma, and Gon and colleagues2 analyzed the incidence and impact of arterial...

Advertisement

Risk of Secondary Cancers After CAR T-Cell Therapy Similar to Previous Standard-of-Care Treatments, Study Finds

Although chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for patients with relapsed and refractory blood cancers, it can also cause an array of immune-related adverse events, including cytokine-release syndrome, immune effector cell–associated neurotoxicity syndrome, and...

ASCO Post X Feed
Social Media Hub by Everwall